{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:51:57Z","timestamp":1788540717549,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.thromres.2008.01.020","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T13:12:44Z","timestamp":1208265164000},"page":"225-230","source":"Crossref","is-referenced-by-count":35,"title":["The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumon"],"prefix":"10.1016","volume":"123","author":[{"given":"Yvonne","family":"van Leeuwen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits R.","family":"Rosendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix. J.M.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2008.01.020_bib1","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1056\/NEJM199612123352407","article-title":"Management of venous thromboembolism","volume":"335","author":"Ginsberg","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2008.01.020_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2008.01.020_bib3","doi-asserted-by":"crossref","first-page":"220S","DOI":"10.1378\/chest.119.1_suppl.220S","article-title":"Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves","volume":"119","author":"Stein","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2008.01.020_bib4","first-page":"263","article-title":"The mechanism of action of oral anticoagulants and its consequences for the practice of oral anticoagulation","volume":"15","author":"Hemker","year":"1985","journal-title":"Haemostasis"},{"key":"10.1016\/j.thromres.2008.01.020_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197904010-00001","article-title":"Clinical pharmacokinetics of oral anticoagulants","volume":"4","author":"Kelly","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.thromres.2008.01.020_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/s-0038-1654292","article-title":"Pharmacokinetics of warfarin following intravenous administration to man","volume":"25","author":"O'Reilly","year":"1971","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.thromres.2008.01.020_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0038-1647630","article-title":"4-hydroxycoumarin oral anticoagulants: pharmacokinetics\u2013response relationship","volume":"60","author":"Thijssen","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.01.020_bib8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.thromres.2008.01.020_bib9","first-page":"1185","article-title":"Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation","volume":"87","author":"Tassies","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2008.01.020_bib10","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.V96.5.1816","article-title":"Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment","volume":"96","author":"Taube","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2008.01.020_bib11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1055\/s-0037-1615385","article-title":"Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?","volume":"80","author":"Barcellona","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.01.020_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.0954-6820.1969.tb01477.x","article-title":"A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon","volume":"186","author":"Breed","year":"1969","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.thromres.2008.01.020_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.0954-6820.1971.tb07471.x","article-title":"Comparative study of the clinical effect of acenocoumarol (Sintrom) and phenprocoumon (Marcoumar) in myocardial infarction and angina pectoris","volume":"190","author":"Fekkes","year":"1971","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.thromres.2008.01.020_bib14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1160\/TH02-10-0179","article-title":"Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon","volume":"90","author":"Fihn","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.01.020_bib15","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1046\/j.1365-2141.2002.03493.x","article-title":"Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon","volume":"117","author":"Gadisseur","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2008.01.020_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0037-1613374","article-title":"Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial","volume":"89","author":"Laporte","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.01.020_bib17","first-page":"188","article-title":"A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol)","volume":"71","author":"Pattacini","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.01.020_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000441-196406000-00003","article-title":"Phenprocoumon, diphenadione, warfarin and bishydroxycoumarin: a comparative study","volume":"247","author":"Rodman","year":"1964","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.thromres.2008.01.020_bib19","first-page":"1559","article-title":"[Oral anticoagulant treatment; which anticoagulant?]","volume":"128","author":"Thijssen","year":"1984","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.thromres.2008.01.020_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0049-3848(99)00222-4","article-title":"Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation","volume":"98","author":"Kristiansen","year":"2000","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.thromres.2008.01.020_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00008571-200401000-00003","article-title":"The risk of overanticoagulation in patients with the cytochrome P450 CYP2C9\u204e2 or CYP2C9\u204e3 alleles on acenocoumarol or phenprocoumon","volume":"14","author":"Visser","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.thromres.2008.01.020_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.clpt.6100036","article-title":"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement","volume":"81","author":"Schalekamp","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384808000558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384808000558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T10:03:52Z","timestamp":1588586632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384808000558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0049384808000558"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2008.01.020","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}